These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2353 related items for PubMed ID: 32929370

  • 1. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL.
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [Abstract] [Full Text] [Related]

  • 2. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z, Wang H, Meng F, Li J, Zhang S.
    J Transl Med; 2015 Jul 29; 13():247. PubMed ID: 26219551
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.
    J Transl Med; 2014 Feb 07; 12():36. PubMed ID: 24502656
    [Abstract] [Full Text] [Related]

  • 5. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H, Shi L, Meng D, Zhou H, Ma J, Wu Y, Wu Y, Gu Y, Xie W, Zhang J, Zhu Y.
    Cancer Treat Res Commun; 2021 Feb 07; 28():100379. PubMed ID: 33951555
    [Abstract] [Full Text] [Related]

  • 6. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C, Guo W, Yost S, Lee JS, Rose D, Avalos C, Ye J, Frankel P, Schmolze D, Waisman J, Lee P, Yuan Y.
    J Immunother Cancer; 2021 Mar 07; 9(3):. PubMed ID: 33757987
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
    Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M.
    Cell Rep; 2018 Mar 13; 22(11):2978-2994. PubMed ID: 29539425
    [Abstract] [Full Text] [Related]

  • 9. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q, Shi G, Chen X, Lin Y, Cheng L, Jiang Q, Yan X, Jiang M, Li Y, Zhang H, Wang H, Wang Y, Wang Q, Zhang Y, Liu Y, Su X, Dai L, Tang M, Li J, Zhang L, Qian Z, Yu D, Deng H.
    Theranostics; 2020 Mar 13; 10(18):8382-8399. PubMed ID: 32724476
    [Abstract] [Full Text] [Related]

  • 10. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D, Ortiz-Espinosa S, Remirez A, Bertolo C, Sainz C, Garcia-Pedrero J, Pio R, Lasarte J, Agorreta J, Montuenga LM, Calvo A.
    J Immunother Cancer; 2021 Mar 13; 9(3):. PubMed ID: 33658304
    [Abstract] [Full Text] [Related]

  • 11. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, Gelbert LM, Shannon HE, Sanchez-Martinez C, De Dios A.
    Drug Metab Dispos; 2015 Sep 13; 43(9):1360-71. PubMed ID: 26149830
    [Abstract] [Full Text] [Related]

  • 12. CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis.
    Nayyar N, de Sauvage MA, Chuprin J, Sullivan EM, Singh M, Torrini C, Zhang BS, Bandyopadhyay S, Daniels KA, Alvarez-Breckenridge C, Dahal A, Brehm MA, Brastianos PK.
    Clin Cancer Res; 2024 Jan 17; 30(2):420-435. PubMed ID: 37611074
    [Abstract] [Full Text] [Related]

  • 13. TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.
    Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Seo SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC.
    Cancer Lett; 2021 Feb 28; 499():137-147. PubMed ID: 33249194
    [Abstract] [Full Text] [Related]

  • 14. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M, Lu J, Zhang G, Wang Y, He M, Xu Q, Xu C, Liu H.
    J Immunother Cancer; 2021 Jan 28; 9(1):. PubMed ID: 33452206
    [Abstract] [Full Text] [Related]

  • 15. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C.
    J Immunother Cancer; 2020 May 28; 8(1):. PubMed ID: 32461345
    [Abstract] [Full Text] [Related]

  • 16. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy.
    Hu C, You W, Kong D, Huang Y, Lu J, Zhao M, Jin Y, Peng R, Hua D, Kuang DM, Chen Y.
    Gastroenterology; 2024 Jun 28; 166(6):1069-1084. PubMed ID: 38445519
    [Abstract] [Full Text] [Related]

  • 17. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B, Wen X, Wang Y, Lin M, Lai J.
    Int Immunopharmacol; 2020 Sep 28; 86():106694. PubMed ID: 32570034
    [Abstract] [Full Text] [Related]

  • 18. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T, Hua C, Yue W, Wu J, Lv X, Wei Q, Zhu S, Zang G, Cui J, Liu YJ, Chen J.
    Pharmacol Res; 2020 Nov 28; 161():105293. PubMed ID: 33176206
    [Abstract] [Full Text] [Related]

  • 19. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells.
    Park S, Oh JH, Park DJ, Zhang H, Noh M, Kim Y, Kim YS, Kim H, Kim YM, Ha SJ, Kwon YG.
    Front Immunol; 2020 Nov 28; 11():620166. PubMed ID: 33584714
    [Abstract] [Full Text] [Related]

  • 20. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y, Wang F, Sun HR, Huang YK, Gao JP, Huang H.
    J Cancer Res Clin Oncol; 2021 Aug 28; 147(8):2209-2222. PubMed ID: 33891173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 118.